Effect of interferon alpha on MHC class II gene expression in ex vivo human islet tissue

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1762, Issue 6, 2006, Pages 627-635

  Harris, Paul E ^a,b   Malanga, Donatella ^a   Liu, Zhuoro ^b   Hardy, Mark A ^b   Souza, Fabiola ^b   Del Pozzo, Giovanna ^a   Winchester, Robert J ^b   Maffei, Antonella ^a,b  

^a INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^b Columbia University Medical School ^*  (United States)

Author keywords

Diabetes; Gene regulation; Human; Interferon ; MHC; Transplantation

Indexed keywords

ALPHA INTERFERON; HLA DQA1 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ALLELE; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; BIOACCUMULATION; CONTROLLED STUDY; DENDRITIC CELL; EX VIVO STUDY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOBLASTOID CELL LINE; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

ALLELES; GENE EXPRESSION REGULATION; GENES, MHC CLASS II; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; INTERFERON-ALPHA; ISLETS OF LANGERHANS; NUCLEAR PROTEINS; PROTEIN ISOFORMS; RNA, MESSENGER; TRANS-ACTIVATORS;

EID: 33745171502     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2006.05.001     Document Type: Article

References (58)

1. Theofilopoulos A.N., Baccala R., Beutler B., and Kono D.H. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu. Rev. Immunol. 23 (2005) 307-335
2. Devendra D., and Eisenbarth G.S. Interferon alpha-a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin. Immunol. 111 (2004) 225
3. Foulis A.K. Interferon-alpha and IDDM: comment. Diabetologia 39 (1996) 127
4. Stewart T.A. Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases. Cytokine Growth Factor Rev. 14 (2003) 139-154
5. Sobel D.O., and Ahvazi B. Alpha-interferon inhibits the development of diabetes in NOD mice. Diabetes 47 (1998) 1867-1872
6. Brod S.A. Ingested type I interferon: a potential treatment for autoimmunity. J. Interferon Cytokine Res. 22 (2002) 1153-1166
7. Brod S.A., Katz S., Phan T., and Stepkowski S. Ingested interferon-alpha prevents allograft islet transplant rejection. Transplantation 69 (2000) 2162-2166
8. Maffei A., Liu Z., Witkowski P., Moschella F., Pozzo G.D., Liu E., Herold K., Winchester R.J., Hardy M.A., and Harris P.E. Identification of tissue-restricted transcripts in human islets. Endocrinology 145 (2004) 4513-4521
9. Lu H., Riley J., Babcock G., Huston M., Stark G., Boss J., and Ransohoff R. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma. J. Exp. Med. 182 (1995) 1517-1525
10. Narendran P., Estella E., and Fourlanos S. Immunology of type 1 diabetes. QJM 98 (2005) 547-556
11. Foulis A.K., Farquharson M.A., and Hardman R. Aberrant expression of class II major histocompatibility complex molecules by B cells and hyperexpression of class I major histocompatibility complex molecules by insulin containing islets in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 30 (1987) 333-343
12. Eisenbarth G.S. Type I diabetes mellitus. A chronic autoimmune disease. N. Engl. J. Med. 314 (1986) 1360-1368
13. Kent S.C., Chen Y., Bregoli L., Clemmings S.M., Kenyon N.S., Ricordi C., Hering B.J., and Hafler D.A. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 435 (2005) 224-228
14. Nakayama M., Abiru N., Moriyama H., Babaya N., Liu E., Miao D., Yu L., Wegmann D.R., Hutton J.C., Elliott J.F., and Eisenbarth G.S. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435 (2005) 220-223
15. Pociot F., and McDermott M.F. Genetics of type 1 diabetes mellitus. Genes Immun. 3 (2002) 235-249
16. Gebe J.A., Swanson E., and Kwok W.W. HLA class II peptide-binding and autoimmunity. Tissue Antigens 59 (2002) 78-87
17. D.W. Gray, To: U. Walter, T. Toepfer, K.E. Dittmar, et al. (2003) Pancreatic NOD beta cells express MHC class II protein and the frequency of I-A(g7) mRNA-expressing beta cells strongly increases during progression to autoimmune diabetes. Diabetologia 46:1106-1114, Diabetologia 47 (2004) 143.
18. Ulrichs K., and Muller-Ruchholtz W. MHC class II antigen expression on the various cells of normal and activated isolated pancreatic islets. Diagn. Immunol. 3 (1985) 47-55
19. Foulis A.K., and Farquharson M.A. Aberrant expression of HLA-DR antigens by insulin-containing beta-cells in recent-onset type I diabetes mellitus. Diabetes 35 (1986) 1215-1224
20. Itoh N., Hanafusa T., Miyazaki A., Miyagawa J., Yamagata K., Yamamoto K., Waguri M., Imagawa A., Tamura S., Inada M., et al. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J. Clin. Invest. 92 (1993) 2313-2322
21. Walter U., Toepfer T., Dittmar K.E., Kretschmer K., Lauber J., Weiss S., Servos G., Lechner O., Scherbaum W.A., Bornstein S.R., Von Boehmer H., and Buer J. Pancreatic NOD beta cells express MHC class II protein and the frequency of I-A(g7) mRNA-expressing beta cells strongly increases during progression to autoimmune diabetes. Diabetologia 46 (2003) 1106-1114
22. Soldevila G., Doshi M., James R., Lake S.P., Sutton R., Gray D., Bottazzo G.F., and Pujol-Borrell R. HLA DR, DP, DQ induction in human islet beta cells by the cytokine combination IFN-gamma + TNF-alpha. Autoimmunity 6 (1990) 307-317
23. Kuttler B., Wanka H., and Hahn H.J. Recognition of islet-directed peripheral blood lymphocytes in vitro before rejection of allogeneic grafted islets. Transplantation 69 (2000) 1987-1990
24. Bouwman L.H., Ling Z., Duinkerken G., Pipeleers D.G., and Roep B.O. HLA incompatibility and immunogenicity of human pancreatic islet preparations cocultured with blood cells of healthy donors. Hum. Immunol. 66 (2005) 494-500
25. Greening J.E., Tree T.I.M., Kotowicz K.T., van Halteren A.G., Roep B.O., Klein N.J., and Peakman M. Processing and presentation of the islet autoantigen GAD by vascular endothelial cells promotes transmigration of autoreactive T-cells. Diabetes 52 (2003) 717-725
26. Marelli-Berg F.M., Frasca L., Weng L., Lombardi G., and Lechler R.I. Antigen recognition influences transendothelial migration of CD4+ T cells. J. Immunol. 162 (1999) 696-703
27. Savinov A.Y., Wong F.S., Stonebraker A.C., and Chervonsky A.V. Presentation of antigen by endothelial cells and chemoattraction are required for homing of insulin-specific CD8+ T cells. J. Exp. Med. 197 (2003) 643-656
28. Kreisel D., Krupnick A.S., Gelman A.E., Engels F.H., Popma S.H., Krasinskas A.M., Balsara K.R., Szeto W.Y., Turka L.A., and Rosengard B.R. Non-hematopoietic allograft cells directly activate CD8+ T cells and trigger acute rejection: an alternative mechanism of allorecognition. Nat. Med. 8 (2002) 233
29. Epperson D.E., and Pober J.S. Antigen-presenting function of human endothelial cells. Direct activation of resting CD8 T cells. J. Immunol. 153 (1994) 5402-5412
30. Ting J.P., and Trowsdale J. Genetic control of MHC class II expression. Cell 109 (2002) S21-S33 Suppl.
31. Masternak K., Muhlethaler-Mottet A., Villard J., Zufferey M., Steimle V., and Reith W. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev. 14 (2000) 1156-1166
32. Accolla R.S., Jotterand-Bellomo M., Scarpellino L., Maffei A., Carra G., and Guardiola J. aIr-1, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression. J. Exp. Med. 164 (1986) 369-374
33. Steimle V., Siegrist C.A., Mottet A., Lisowska-Grospierre B., and Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 265 (1994) 106-109
34. LeibundGut-Landmann S., Waldburger J.M., Krawczyk M., Otten L.A., Suter T., Fontana A., Acha-Orbea H., and Reith W. Mini-review: specificity and expression of CIITA, the master regulator of MHC class II genes. Eur. J. Immunol. 34 (2004) 1513-1525
35. Suter T., Malipiero U., Otten L., Ludewig B., Muelethaler-Mottet A., Mach B., Reith W., and Fontana A. Dendritic cells and differential usage of the MHC class II transactivator promoters in the central nervous system in experimental autoimmune encephalitis. Eur. J. Immunol. 30 (2000) 794-802
36. Kwak B., Mulhaupt F., Myit S., and Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 6 (2000) 1399-1402
37. Piskurich J.F., Gilbert C.A., Ashley B.D., Zhao M., Chen H., Wu J., Bolick S.C., and Wright K.L. Expression of the MHC class II transactivator (CIITA) type IV promoter in B lymphocytes and regulation by IFN-gamma. Mol. Immunol. 43 (2006) 519-528
38. Honey K., and Rudensky A. The pIV-otal class II transactivator promoter regulates major histocompatibility complex class II expression in the thymus. J. Exp. Med. 194 (2001) 15F-18F
39. Muczynski K.A., Ekle D.M., Coder D.M., and Anderson S.K. Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. J. Am. Soc. Nephrol. 14 (2003) 1336-1348
40. Friese M.A., Jones E.Y., and Fugger L. MHC II molecules in inflammatory diseases: interplay of qualities and quantities. Trends Immunol. 26 (2005) 559-561
41. Guardiola J., Maffei A., Lauster R., Mitchison N.A., Accolla R.S., and Sartoris S. Functional significance of polymorphism among MHC class II gene promoters. Tissue Antigens 48 (1996) 615-625
42. Swanberg M., Lidman O., Padyukov L., Eriksson P., Akesson E., Jagodic M., Lobell A., Khademi M., Borjesson O., Lindgren C.M., Lundman P., Brookes A.J., Kere J., Luthman H., Alfredsson L., Hillert J., Klareskog L., Hamsten A., Piehl F., and Olsson T. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat. Genet. 37 (2005) 486-494
43. Maffei A., Harris P.E., Reed E.F., Del Pozzo G., Ciullo M., Suciu-Foca N., and Guardiola J. Differential expression of insulin-dependent diabetes mellitus-associated HLA-DQA1 alleles in vivo. Eur. J. Immunol. 27 (1997) 1549-1556
44. Beaty J.S., West K.A., and Nepom G.T. Functional effects of a natural polymorphism in the transcriptional regulatory sequence of HLA-DQB1. Mol. Cell. Biol. 15 (1995) 4771-4782
45. Shapiro A.M., Lakey J.R., Ryan E.A., Korbutt G.S., Toth E., Warnock G.L., Kneteman N.M., and Rajotte R.V. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343 (2000) 230-238
46. Linetsky E., Selvaggi G., Bottino R., Kong S.S., Qian T., Alejandro R., and Ricordi C. Comparison of collagenase type P and Liberase during human islet isolation using the automated method. Transplant. Proc. 27 (1995) 3264
47. Lakey J.R., Warnock G.L., Shapiro A.M., Korbutt G.S., Ao Z., Kneteman N.M., and Rajotte R.V. Intraductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion. Cell Transplant 8 (1999) 285-292
48. Lakey J.R., Warnock G.L., Rajotte R.V., Suarez-Alamazor M.E., Ao Z., Shapiro A.M., and Kneteman N.M. Variables in organ donors that affect the recovery of human islets of Langerhans. Transplantation 61 (1996) 1047-1053
49. Moschella F., Bisikirska B., Maffei A., Papadopoulos K.P., Skerrett D., Liu Z., Hesdorffer C.S., and Harris P.E. Gene expression profiling and functional activity of human dendritic cells induced with IFN-alpha-2b: implications for cancer immunotherapy. Clin. Cancer Res. 9 (2003) 2022-2031
50. Maffei A., Ayello J., Skerrett D., Papadopoulos K., Harris P., and Hesdorffer C. A novel closed system utilizing styrene copolymer bead adherence for the production of human dendritic cells. Transfusion 40 (2000) 1419-1420
51. Rozen S., and Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 132 (2000) 365-386
52. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Ann. Rev. Biochem. 67 (1998) 227-264
53. Paquette R.L., Hsu N.C., Kiertscher S.M., Park A.N., Tran L., Roth M.D., and Glaspy J.A. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J. Leukoc. Biol. 64 (1998) 358-367
54. Otten L.A., Steimle V., Bontron S., and Mach B. Quantitative control of MHC class II expression by the transactivator CIITA. Eur. J. Immunol. 28 (1998) 473-478
55. Deffrennes V., Vedrenne J., Stolzenberg M.-C., Piskurich J., Barbieri G., Ting J.P., Charron D., and Alcaide-Loridan C. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter. J. Immunol. 167 (2001) 98-106
56. Pestka S., Krause C.D., and Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202 (2004) 8-32
57. Ji X., Cheung R., Cooper S., Li Q., Greenberg H.B., and He X.S. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology 37 (2003) 610-621
58. Pascual V., Banchereau J., and Palucka A.K. The central role of dendritic cells and interferon-alpha in SLE. Curr. Opin. Rheumatol. 15 (2003) 548-556